Download PDF
Int J Angiol 2018; 27(04): 213-222
DOI: 10.1055/s-0038-1673660
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Advanced Glycation End Products:Receptors for Advanced Glycation End Products Axis in Coronary Stent Restenosis: A Prospective Study

Colin Pearce
1   Division of Cardiology, Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
,
Naorin Islam
2   Department of Community Health and Epidemiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
,
Robyn Bryce
2   Department of Community Health and Epidemiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
,
Erick Donnell McNair
3   Department of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
29 October 2018 (online)

    Permissions and Reprints

Corrected by:

Erratum to: Advanced Glycation End Products: Receptors for Advanced Glycation End Products Axis in Coronary Stent Restenosis: A Prospective StudyInt J Angiol 2018; 27(04): e1-e1
DOI: 10.1055/s-0038-1676383

Abstract

This study was aimed to correlate the pre- and 6-month postpercutaneous coronary intervention (PCI) serum concentrations of advanced glycation end products (AGE), soluble receptors for advanced glycation end products (sRAGE), AGE/sRAGE ratio, and serum malondialdehyde (MDA) levels with in-stent restenosis (ISR) among patients receiving either a drug-eluting stent (DES) or a bare-metal stent (BMS).In-stent restenosis remains as an adverse outcome following PCI. Sixty consecutive nondiabetic, Caucasian male patients, diagnosed with a non-ST-elevation myocardial infarction who received either a DES or BMS via PCI, were enrolled. Baseline levels of serum AGE, sRAGE, AGE/sRAGE ratios, MDA, and angiographic parameters were determined at stenting and at 6 months. Patients with and without ISR at 6 months were compared on both baseline and 6-month biomarker levels and within stent types.The pre-PCI serum AGE levels and AGE/sRAGE ratios were higher in ISR patients compared with non-ISR patients, while the pre-PCI and post-PCI serum sRAGE levels were lower in ISR patients compared with non-ISR patients. The pre and post-PCI levels of MDA were also higher in ISR patients. Comparing stent types, relative levels of MDA between those with and without ISR at the respective time points were similar, although changes between time points appeared type specific.Post-PCI ISR correlates with low serum values of sRAGE and high serum values of AGE, MDA, and AGE/sRAGE ratio which are present at stenting. The associations of baseline AGE, sRAGE, AGE/sRAGE, and MDA levels with ISR appear consistent between stent types.

Keywords

PCI - stent - restenosis - cardiac Biomarkers - advancedglycation end products - soluble receptor for advanced glycation end products - oxidative stress

Supplementary Material

 

  • References

  • 1 Cassese S, Byrne RA, Tada T. , et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 2014; 100 (02) 153-159
    CrossrefPubMedGoogle Scholar
  • 2 Stone GW, Ellis SG, Cox DA. , et al; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350 (03) 221-231
    CrossrefPubMedGoogle Scholar
  • 3 McNair ED, Wells CR, Mabood Qureshi A. , et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. ClinCardiol 2010; 33 (11) 678-6855
    PubMedGoogle Scholar
  • 4 Hunt JV, Smith CC, Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990; 39 (11) 1420-1424
    CrossrefPubMedGoogle Scholar
  • 5 Prasad K, Bharadwaj LA. Hydroxyl radical--a mediator of acetylcholine-induced vascular relaxation. J Mol Cell Cardiol 1996; 28 (09) 2033-2041
    CrossrefPubMedGoogle Scholar
  • 6 Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63 (04) 582-592
    CrossrefPubMedGoogle Scholar
  • 7 Zhou Z, Wang K, Penn MS. , et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003; 107 (17) 2238-2243
    CrossrefPubMedGoogle Scholar
  • 8 Sakaguchi T, Yan SF, Yan SD. , et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111 (07) 959-972
    CrossrefPubMedGoogle Scholar
  • 9 Spadaccio C, Patti G, De Marco F. , et al. Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study). Am J Cardiol 2013; 112 (01) 21-26
    CrossrefPubMedGoogle Scholar
  • 10 Falcone C, Emanuele E, D'Angelo A. , et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. ArteriosclerThrombVascBiol 2005; 25 (05) 1032-1037
    PubMedGoogle Scholar
  • 11 Aronson D. Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Med Hypotheses 2002; 59 (03) 297-301
    CrossrefPubMedGoogle Scholar
  • 12 Juni RP, Duckers HJ, Vanhoutte PM, Virmani R, Moens AL. Oxidative stress and pathological changes after coronary artery interventions. J Am CollCardiol 2013; 61 (14) 1471-1481
    CrossrefPubMedGoogle Scholar
  • 13 Yonny ME, García EM, López A, Arroquy JI, Nazareno MA. Measurement of malondialdehyde as oxidative stress biomarker in goat plasma by HPLC-DAD. Microchem J 2016; 129: 281-285
    CrossrefPubMedGoogle Scholar
  • 14 McNair E. Homocysteine and malondialdehyde as predictors of restenosis following percutaneous coronary intervention. Available from: http://www.openthesis.org/documents/Homocysteine-Malondialdehyde-as-Predictors-Restenosis-216736.html ; accessed September 4 2018
    PubMedGoogle Scholar
  • 15 Zhang Y-J, Bourantas CV, Muramatsu T. , et al. Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial. EuroIntervention 2014; 10 (06) 672-680
    CrossrefPubMedGoogle Scholar
  • 16 Yagi K. Assay for blood plasma or serum. In: Pyle AM, Christianson DW. eds. Methods in Enzymology. Vol 105. NY, USA: Elsevier; 1984: 328-331
    Google Scholar
  • 17 Zargham R. Preventing restenosis after angioplasty: a multistage approach. ClinSci (Lond) 2008; 114 (04) 257-264
    PubMedGoogle Scholar
  • 18 Stirban A, Gawlowski T, Roden M. Vascular effects of advanced glycationendproducts: Clinical effects and molecular mechanisms. MolMetab 2013; 3 (02) 94-108
    PubMedGoogle Scholar
  • 19 Basta G, Del Turco S, Navarra T. , et al. Inverse association between circulating levels of soluble receptor for advanced glycation end-products and coronary plaque burden. J AtherosclerThromb 2012; 19 (10) 941-948
    PubMedGoogle Scholar
  • 20 Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 2010; 106 (05) 842-853
    CrossrefPubMedGoogle Scholar
  • 21 Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 2003; 108 (17) 2034-2040
    CrossrefPubMedGoogle Scholar
  • 22 Chen Z, Keaney Jr JF, Schulz E. , et al. Decreased neointimal formation in Nox2-deficient mice reveals a direct role for NADPH oxidase in the response to arterial injury. ProcNatlAcadSci U S A 2004; 101 (35) 13014-13019
    CrossrefPubMedGoogle Scholar
  • 23 Kavitha S, Sridhar MG, Santhosh S. Oxidative Stress and Coronary Stenting. Innov J Med Health Sci 2015; 5 (04) 146-149
    PubMedGoogle Scholar
  • 24 Shigematsu S, Takahashi N, Hara M, Yoshimatsu H, Saikawa T. Increased incidence of coronary in-stent restenosis in type 2 diabetic patients is related to elevated serum malondialdehyde-modified low-density lipoprotein. Circ J 2007; 71 (11) 1697-1702
    CrossrefPubMedGoogle Scholar
  • 25 Price MJ. Coronary Stenting: A Companion to Topol's Textbook of Interventional Cardiology E-Book. Philadelphia, PA: Elsevier/Saunders; 2013
    Google Scholar
  • 26 Inoue T, Kato T, Hikichi Y. , et al. Stent-induced neutrophil activation is associated with an oxidative burst in the inflammatory process, leading to neointimal thickening. ThrombHaemost 2006; 95 (01) 43-48
    PubMedGoogle Scholar
  • 27 Nozue T, Yamagishi S, Takeuchi M. , et al. Effect of statins on the serum soluble form of receptor for advanced glycation end-products and its association with coronary atherosclerosis in patients with angina pectoris. IJC MetabEndocr 2014; 4: 47-52
    PubMedGoogle Scholar